Holistic Financial Partners Has $204,000 Stock Position in Merck & Co., Inc. $MRK

Holistic Financial Partners lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 41.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,575 shares of the company’s stock after selling 1,834 shares during the quarter. Holistic Financial Partners’ holdings in Merck & Co., Inc. were worth $204,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Merck & Co., Inc. by 0.6% during the first quarter. Vanguard Group Inc. now owns 252,513,381 shares of the company’s stock worth $22,665,601,000 after acquiring an additional 1,417,274 shares in the last quarter. Wellington Management Group LLP raised its position in Merck & Co., Inc. by 1.1% during the first quarter. Wellington Management Group LLP now owns 81,669,651 shares of the company’s stock worth $7,330,668,000 after acquiring an additional 927,621 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Merck & Co., Inc. by 144.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock worth $4,418,820,000 after acquiring an additional 29,104,112 shares in the last quarter. Amundi raised its position in Merck & Co., Inc. by 37.1% during the first quarter. Amundi now owns 13,077,716 shares of the company’s stock worth $1,130,397,000 after acquiring an additional 3,542,036 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Merck & Co., Inc. during the first quarter worth $991,553,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Monday. Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company reduced their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Hold” and a consensus price target of $104.47.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $82.51 on Tuesday. The firm has a market capitalization of $206.09 billion, a PE ratio of 12.71, a PEG ratio of 0.95 and a beta of 0.37. The company’s 50-day moving average is $84.51 and its 200-day moving average is $81.89. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $105.07. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.22. The company had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company’s revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.57 earnings per share. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.